LIFECORE BIOMEDICAL, INC. Interest Costs Capitalized
LIFECORE BIOMEDICAL, INC. (LFCR) reported Interest Costs Capitalized of $52.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InterestCostsCapitalized · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for the quarter ending 2026-06-30 was $52.00K.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for the quarter ending 2026-03-31 was $25.00K.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for the quarter ending 2025-09-30 was $572.00K.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for the quarter ending 2025-05-25 was $796.00K.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for fiscal 2025 was $3.05M, a 3.21% decline from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for fiscal 2024 was $3.15M, a 12.50% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for fiscal 2023 was $3.60M, a 71.43% increase from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. interest costs capitalized for fiscal 2022 was $2.10M, a 16.67% increase from fiscal 2021.
| Period end | Interest Costs Capitalized 3 month | Interest Costs Capitalized 6 month | Interest Costs Capitalized 7 month | Interest Costs Capitalized 9 month | Interest Costs Capitalized 12 month | Interest Costs Capitalized 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $52.00K 10-Q · filed 2026-08-05 | $77.00K 10-Q · filed 2026-08-05 | ||||
| 2026-03-31 | $25.00K 10-Q · filed 2026-05-06 | |||||
| 2025-12-31 | $903.00K 10-KT · filed 2026-03-16 | |||||
| 2025-09-30 | $572.00K 10-Q · filed 2025-11-06 | |||||
| 2025-05-25 | $796.00K 10-Q · filed 2026-08-05 | $1.59M 10-Q · filed 2026-08-05 | $2.34M derived: sum of 3 quarters · filed 2026-08-05 | $3.05M 10-KT · filed 2026-03-16 | ||
| 2025-02-23 | $798.00K 10-Q · filed 2026-05-06 | $1.54M derived: sum of 2 quarters · filed 2026-05-06 | $2.25M 10-Q · filed 2025-04-03 | $2.15M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-11-24 | $745.00K 10-Q · filed 2025-01-02 | $1.46M 10-Q · filed 2025-01-02 | $1.36M derived: sum of 3 quarters · filed 2026-03-16 | $2.54M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-08-25 | $711.00K 10-Q · filed 2025-11-06 | $611.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.80M derived: sum of 3 quarters · filed 2026-03-16 | $2.89M derived: sum of 4 quarters · filed 2026-03-16 | ||
| 2024-05-26 | -$100.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $1.09M derived: sum of 2 quarters · filed 2026-03-16 | $2.18M derived: sum of 3 quarters · filed 2026-03-16 | $3.15M 10-KT · filed 2026-03-16 | $3.20M 10-K · filed 2024-08-26 | |
| 2024-02-25 | $1.19M 10-Q · filed 2025-04-03 | $2.28M derived: sum of 2 quarters · filed 2025-04-03 | $3.25M 10-Q · filed 2025-04-03 | |||
| 2023-11-26 | $1.09M 10-Q · filed 2025-01-02 | $2.06M 10-Q · filed 2025-01-02 | ||||
| 2023-08-27 | $969.00K 10-Q · filed 2024-10-04 | |||||
| 2023-05-28 | $3.60M 10-K · filed 2024-08-26 | |||||
| 2022-05-29 | $2.10M 10-K · filed 2024-08-26 | $400.00K 10-K · filed 2022-09-14 | ||||
| 2021-05-30 | $1.80M 10-K · filed 2024-03-20 | $500.00K 10-K · filed 2021-07-29 | ||||
| 2020-05-31 | $400.00K 10-K/A · filed 2023-03-16 | $1.20M 10-K · filed 2020-08-14 | ||||
| 2019-05-26 | $700.00K 10-K · filed 2021-07-29 | |||||
| 2018-05-27 | $600.00K 10-K · filed 2020-08-14 | $563.00K 10-K · filed 2018-08-09 | ||||
| 2017-05-28 | $500.00K 10-K · filed 2019-08-01 | $514.00K 10-K · filed 2017-08-11 | ||||
| 2016-05-29 | $487.00K 10-K · filed 2018-08-09 | |||||
| 2015-05-31 | $45.00K 10-K/A · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |